Skip to content

Sickle Cell Uric Acid (SCUA) - Cohort Repository

Sickle Cell Uric Acid (SCUA) - Cohort Repository

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04190888
Enrollment
78
Registered
2019-12-09
Start date
2019-07-01
Completion date
2021-12-31
Last updated
2022-02-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Kidney Diseases, Sickle Cell Disease

Keywords

Uric acid

Brief summary

The purpose of this research is to study the causes of Sickle Cell kidney disease, as well as to collect and store samples and information about people with Sickle Cell Disease.

Detailed description

Sickle Cell Disease causes kidney injury over time, but it is not clear why some individuals have very significant chronic kidney disease and why some do not. The purpose of this research is to study whether having high levels of 'uric acid,' which is a naturally occurring molecule in the body that may increase kidney injury and systemic inflammation, accelerates the progression of chronic kidney disease over time. Researchers will measure the number of participants that have high uric acid levels at the beginning of the study, as well as the number of participants that develop new high levels throughout the study. The study will also try to determine what causes the high uric acid levels in some patients but not others. The results of this study could help understand kidney injury and uric acid in sickle cell disease better.

Interventions

OTHERNo intervention

No intervention - observational study

Sponsors

Virginia Commonwealth University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
5 Years to 29 Years
Healthy volunteers
No

Inclusion criteria

* Age 5-29 years * Sickle cell disease as diagnosed by hemoglobin electrophoresis, or by newborn screen per standard of care * Currently receiving comprehensive sickle cell care at the Children's Hospital of Richmond at VCU or in the adult Internal Medicine sickle cell care clinic at VCU.

Exclusion criteria

* Those who have received organ, stem cell, or bone marrow transplantation. - Those who require chronic dialysis

Design outcomes

Primary

MeasureTime frameDescription
Percentage of participants in the sample with hyperuricemiaBaseline(i.e. high uric acid levels) out of all patients with a uric acid level measured at baseline.
Incidence rate of hyperuricemia per yearBaseline to year 5Calculate the incidence rate of new cases of hyperuricemia per year in each year of the cohort study
The mean rate of change of estimated glomerular filtration rate (eGFR) per year in those with hyperuricemia and those with normouricemiaBaseline to year 5Determine the mean rate of change of eGFR per year for each group.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026